NASDAQ:TOVX 16 October 2025 - 24 October 2025

Theriva shares surged 92% intraday Oct. 15 after its VCN-01 therapy met primary endpoints in a Phase 2b pancreatic cancer trial, then fell back following a $4 million equity raise. Median survival in a two-dose subgroup reached 14.8 months versus 11.6 for chemo alone. The company held $12.1 million cash as of June 30, 2025, funding operations into early 2026. Expanded trial results will be presented at ESMO Oct. 20.

Theriva Biologics shares jumped 92% to $0.84 on October 15, 2025, after its VCN-01 therapy met key endpoints in a Phase 2b trial for metastatic pancreatic cancer. Shares fell back to the mid-$0.40s the next day after a $4 million financing deal. Detailed trial results will be presented at the ESMO conference on October 20.